These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat. Abalo R; Chen C; Vera G; Fichna J; Thakur GA; López-Pérez AE; Makriyannis A; Martín-Fontelles MI; Storr M Neurogastroenterol Motil; 2015 Dec; 27(12):1721-35. PubMed ID: 26387676 [TBL] [Abstract][Full Text] [Related]
10. Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. Camilleri M; Carlson P; McKinzie S; Grudell A; Busciglio I; Burton D; Baxter K; Ryks M; Zinsmeister AR Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G13-9. PubMed ID: 17962356 [TBL] [Abstract][Full Text] [Related]
11. Cannabinoid pharmacology and therapy in gut disorders. Uranga JA; Vera G; Abalo R Biochem Pharmacol; 2018 Nov; 157():134-147. PubMed ID: 30076849 [TBL] [Abstract][Full Text] [Related]
12. Methods evaluating cannabinoid and endocannabinoid effects on gastrointestinal functions. Darmani NA Methods Mol Med; 2006; 123():169-89. PubMed ID: 16506408 [TBL] [Abstract][Full Text] [Related]
13. Cannabinoids and the digestive tract. Izzo AA; Coutts AA Handb Exp Pharmacol; 2005; (168):573-98. PubMed ID: 16596788 [TBL] [Abstract][Full Text] [Related]
14. Cannabinoids and the gut: new developments and emerging concepts. Izzo AA; Sharkey KA Pharmacol Ther; 2010 Apr; 126(1):21-38. PubMed ID: 20117132 [TBL] [Abstract][Full Text] [Related]
15. Endocannabinoids and the gut. Pinto L; Capasso R; Di Carlo G; Izzo AA Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):333-41. PubMed ID: 12052047 [TBL] [Abstract][Full Text] [Related]
16. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice. Cluny NL; Keenan CM; Duncan M; Fox A; Lutz B; Sharkey KA J Pharmacol Exp Ther; 2010 Sep; 334(3):973-80. PubMed ID: 20571060 [TBL] [Abstract][Full Text] [Related]
17. Cannabis and cannabinoids: pharmacology and rationale for clinical use. Pertwee RG Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of GPR55, a putative cannabinoid receptor. Sharir H; Abood ME Pharmacol Ther; 2010 Jun; 126(3):301-13. PubMed ID: 20298715 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Calignano A; La Rana G; Makriyannis A; Lin SY; Beltramo M; Piomelli D Eur J Pharmacol; 1997 Dec; 340(2-3):R7-8. PubMed ID: 9537804 [TBL] [Abstract][Full Text] [Related]
20. Role of cannabinoid receptors in the control of gastrointestinal motility and perception. Fioramonti J; Bueno L Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):385-97. PubMed ID: 19072387 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]